Provided by Tiger Trade Technology Pte. Ltd.

NEUROGENE INC

37.87
+1.634.50%
Post-market: 37.870.00000.00%16:29 EDT
Volume:134.48K
Turnover:5.03M
Market Cap:757.83M
PE:-7.51
High:38.21
Open:35.80
Low:35.31
Close:36.24
52wk High:43.66
52wk Low:15.93
Shares:20.01M
Float Shares:11.34M
Volume Ratio:0.62
T/O Rate:1.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.0440
EPS(LYR):-4.2400
ROE:-45.32%
ROA:-27.97%
PB:3.49
PE(LYR):-8.93

Loading ...

Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of Ngn-401 Gene Therapy for Rett Syndrome

THOMSON REUTERS
·
Jun 29

Neurogene - Ngn-401 Generally Well-tolerated at 1E15 Vg Dose as of June 16, 2026

THOMSON REUTERS
·
Jun 29

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), HeartFlow, Inc. (HTFL) and Neurogene (NGNE)

TIPRANKS
·
Jun 11

Neurogene Price Target Maintained With a $70.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 09

Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Lyell Immunopharma (LYEL)

TIPRANKS
·
Jun 08

Neurogene Completes Enrollment in Embolden Trial of NGN-401

MT Newswires Live
·
Jun 08

Neurogene - Topline Data From Embolden Trial Anticipated in Second Half of 2027 - SEC Filing

THOMSON REUTERS
·
Jun 08

Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of Ngn-401 for Rett Syndrome

THOMSON REUTERS
·
Jun 08

Neurogene shareholders elect Baffi, Palekar as Class III directors

Reuters
·
Jun 05

Neurogene initiated with a Buy at Rodman & Renshaw

TIPRANKS
·
Jun 03

Neurogene issues inducement stock options for 17,045 shares to new hires

Reuters
·
Jun 03

Analysts Offer Insights on Healthcare Companies: Alpha Tau Medical Ltd (DRTS), Neurogene (NGNE) and Milestone Pharmaceuticals (MIST)

TIPRANKS
·
May 27

LifeSci Capital Sticks to Its Buy Rating for Neurogene (NGNE)

TIPRANKS
·
May 16

Analysts Are Bullish on Top Healthcare Stocks: Acurx Pharmaceuticals (ACXP), Neurogene (NGNE)

TIPRANKS
·
May 13

Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Neurogene (NGNE) and Stereotaxis (STXS)

TIPRANKS
·
May 13

Neurogene Q1 EPS $(1.39) Misses $(1.36) Estimate

Benzinga Earnings
·
May 13

Neurogene posts corporate deck highlighting NGN-401 gene therapy program for Rett syndrome

Reuters
·
May 13

Neurogene Q1 net loss widens on higher R&D costs

Reuters
·
May 13

Neurogene Q1 FY26 net loss widens to USD 30.9 million

Reuters
·
May 13

BRIEF-Neurogene Q1 Operating Expenses USD 33.349 Million

Reuters
·
May 13